LKC Technologies

LKC Technologies is a long-established, privately-held leader in the niche but critical field of ophthalmic electrophysiology diagnostics. The company's core value proposition is providing objective, functional data on retinal health through its portable and user-friendly ERG/VEP devices, which complement structural imaging to improve disease diagnosis, monitoring, and management. Its recent acquisition by AMETEK in 2026 provides significant financial backing and strategic synergies with AMETEK's broader ophthalmic portfolio, positioning LKC for accelerated growth. The company is capitalizing on a growing clinical recognition, evidenced by inclusion in major practice guidelines, that functional testing is essential for comprehensive eye care, particularly in high-prevalence conditions like diabetic retinopathy.

Portable, non-mydriatic Electroretinography (ERG) and Visual Evoked Potential (VEP) testing systems for objective functional assessment of retinal and visual pathway health. Platform includes FDA-cleared, ISCEV-compliant devices (RETeval) designed for clinical and research use in human and veterinary medicine.

LKC holds a unique position with the only FDA-cleared, portable, non-mydriatic ERG device. It faces competition from traditional, bulky lab-based electrophysiology systems (e.g., Diagnosys, Roland Consult) and broader competitive pressure from large ophthalmic imaging companies (Heidelberg, Topcon) that could develop functional add-ons. Its partnership with AMETEK strengthens its competitive moat.